{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:48:35Z","timestamp":1776995315660,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.034","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T17:34:31Z","timestamp":1359221671000},"page":"185-189","source":"Crossref","is-referenced-by-count":21,"title":["Immunoadsorption for connective tissue disease"],"prefix":"10.1016","volume":"14","author":[{"given":"B.","family":"Hohenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keg069","article-title":"Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems","volume":"42","author":"Sultan","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/art.1780220504","article-title":"Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus","volume":"22","author":"Wilson","year":"1979","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2010.07.007","article-title":"The blood nucleome in the pathogenesis of SLE","volume":"10","author":"Pisetsky","year":"2010","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib6","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clim.2006.02.006","article-title":"Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)","volume":"120","author":"Servettaz","year":"2006","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"Henault","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.berh.2007.10.002","article-title":"Mixed connective tissue disease: what is behind the curtain?","volume":"21","author":"Aringer","year":"2007","journal-title":"Best Practice and Research Clinical Rheumatology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/0961203302lu144oa","article-title":"Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients","volume":"11","author":"Furtado","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/art.21566","article-title":"A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen","volume":"54","author":"Greidinger","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1172\/JCI108447","article-title":"Antibody-dependent cell-mediated cytotoxicity in selected autoimmune diseases","volume":"58","author":"Feldmann","year":"1976","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jca.20302","article-title":"Conventional apheresis therapies: a review","volume":"26","author":"Ward","year":"2011","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jca.2920070314","article-title":"Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group","volume":"7","author":"Lewis","year":"1992","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1","article-title":"Randomized controlled trial of pulse\/synchronization cyclophosphamide\/apheresis for proliferative lupus nephritis","volume":"13","author":"Wallace","year":"1998","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(199803)41:3<414::AID-ART6>3.0.CO;2-N","article-title":"Severe infections in plasmapheresis-treated systemic lupus erythematosus","volume":"41","author":"Aringer","year":"1998","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib18","first-page":"307","article-title":"Therapy of lupus nephritis. A two-year prospective study","volume":"145","author":"Doria","year":"1994","journal-title":"Annales de medecine interne"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/jaut.1998.0229","article-title":"Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus","volume":"11","author":"Gaubitz","year":"1998","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1526-0968.2001.00370.x","article-title":"Background and indications for protein A-based extracorporeal immunoadsorption","volume":"5","author":"Matic","year":"2001","journal-title":"Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0006-291X(80)91255-3","article-title":"Immune complex formation enhances the binding of staphylococcal protein A to immunoglobulin G","volume":"94","author":"Langone","year":"1980","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1526-0968.2003.00017.x","article-title":"Peptide based adsorbers for therapeutic immunoadsorption","volume":"7","author":"Ronspeck","year":"2003","journal-title":"Therapeutic Apheresis and Dialysis: Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1744-9987.1998.tb00093.x","article-title":"Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins","volume":"2","author":"Koll","year":"1998","journal-title":"Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib24","first-page":"S61","article-title":"Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy","volume":"64","author":"Schneider","year":"1998","journal-title":"Kidney International Supplement"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/rheumatology\/40.5.513","article-title":"Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?","volume":"40","author":"Schmaldienst","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1567-5688(09)71823-9","article-title":"Immunoadsorption for systemic lupus erythematosus","volume":"10","author":"Stummvoll","year":"2009","journal-title":"Atherosclerosis Supplements"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1567-5688(09)71824-0","article-title":"Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity","volume":"10","author":"Biesenbach","year":"2009","journal-title":"Atherosclerosis Supplements"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203310389487","article-title":"Immunoadsorption (IAS) for systemic lupus erythematosus","volume":"20","author":"Stummvoll","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0961203311426569","article-title":"Current state of evidence on \u2018off-label\u2019 therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland\u2013a consensus report","volume":"21","author":"Aringer","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","author":"Fernandez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2004.029660","article-title":"IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study","volume":"64","author":"Stummvoll","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00508-004-0232-8","article-title":"Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy","volume":"116","author":"Stummvoll","year":"2004","journal-title":"Wiener klinische Wochenschrift"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfr239","article-title":"Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity","volume":"27","author":"Stummvoll","year":"2012","journal-title":"Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association \u2013 European Renal Association"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib35","doi-asserted-by":"crossref","first-page":"214013","DOI":"10.1155\/2011\/214013","article-title":"B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence","volume":"2011","author":"Daoussis","year":"2011","journal-title":"International Journal of Rheumatology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0b013e3283310d57","article-title":"Disease-modifying treatment in systemic sclerosis: current status","volume":"21","author":"Quillinan","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1468-1331.2002.00447_10.x","article-title":"Severe dermatomyositis with rhabdomyolysis and paralytic ileus: a case successfully treated with plasmapheresis and intravenous immunoglobulin","volume":"9","author":"Fukunaga","year":"2002","journal-title":"European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2169\/internalmedicine.39.1119","article-title":"Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis","volume":"39","author":"Seguchi","year":"2000","journal-title":"Internal Medicine"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/kei271","article-title":"Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease","volume":"45","author":"Rech","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.atherosclerosissup.2012.10.034_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1744-9987.2008.00597.x","article-title":"A case report of successful treatment with immunoadsorption onto protein A in mixed connective tissue disease in childhood","volume":"12","author":"Rummler","year":"2008","journal-title":"Therapeutic Apheresis and Dialysis: Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T05:32:00Z","timestamp":1539927120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000451"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.034","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}